Loading…
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study
Purpose Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients’ quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospect...
Saved in:
| Published in: | Supportive care in cancer 2022-08, Vol.30 (8), p.6955-6961 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c2876-6e3db47b557978daf8dfc9f16f6aa3cb322fdf18b644d247195070aa808da903 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c2876-6e3db47b557978daf8dfc9f16f6aa3cb322fdf18b644d247195070aa808da903 |
| container_end_page | 6961 |
| container_issue | 8 |
| container_start_page | 6955 |
| container_title | Supportive care in cancer |
| container_volume | 30 |
| creator | Pedersini, Rebecca Zamparini, Manuel Bosio, Sara di Mauro, Pierluigi Turla, Antonella Monteverdi, Sara Zanini, Alessandra Amoroso, Vito Vassalli, Lucia Cosentini, Deborah Grisanti, Salvatore Simoncini, Edda Lucia Berruti, Alfredo |
| description | Purpose
Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients’ quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospectively evaluate the characteristics of TAs in early breast cancer (EBC) patients during (neo)adjuvant chemotherapy and up to 1 year after its completion.
Methods
From April 2014 to June 2018, 182 EBC patients entered the study and received (neo)adjuvant chemotherapy, mostly with taxane and anthracycline-containing regimens (65% of cases). A dietitian performed TAs assessment through the Common Terminology Criteria for Adverse Event v4.0 (CTCAE) and the Chemotherapy-induced Taste Alteration Scale (CiTAS) questionnaire during chemotherapy and follow-up according to defined time points: at baseline (T0, before starting chemotherapy); at the first follow-up visit, (T1, 2 months after starting chemotherapy); at the final follow-up visit (T2, 1 week after completing chemotherapy); after that, every 3 months up to 12 months.
Results
Dysgeusia was reported by 69.8% of patients at T1 and declined subsequently; salty flavor distortion was the most frequently reported TA (51.6% of cases). CiTAS was significantly different between T0 and T2 (
p
|
| doi_str_mv | 10.1007/s00520-022-07091-6 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2662538448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A707943171</galeid><sourcerecordid>A707943171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2876-6e3db47b557978daf8dfc9f16f6aa3cb322fdf18b644d247195070aa808da903</originalsourceid><addsrcrecordid>eNp9kstu1DAUhi0EotPCC7BAltiwcetb4oRdVUFBqsRm9pbjS-uR4wQ7KZrH6BtzhilFIIS9sHTOd36fG0JvGD1nlKqLSmnDKaGcE6poz0j7DG2YFIIoIfrnaEN7yYgUTXOCTmvdUcqUavhLdAIm0QmuNuhha-risUmLL2aJU67YrSXmW5z9dGHcbr03ecH2zo_TcgfMvMcmO1zXofpvqwdfmFKavpN1xjHjoXgQxNZk6wueQRKQ-gEbPJepzt4u8d7jCh8kTyz4gLIp5mhNwnVZ3f4VehFMqv7143uGtp8-bq8-k5uv11-uLm-I5Z1qSeuFG6Qamkb1qnMmdC7YPrA2tMYIOwjOgwusG1opHZeK9Q00yZiOAtxTcYbeH2UhL6ijLnqM1fqUDBS-Vs3blkOTpOwAffcXupvWkiE5oFTXd52A80TdmuR1zGFairEHUX2pqOqlYIoBdf4PCq7zY7RT9iGC_Y8Afgyw0L9afNBziaMpe82oPqyBPq6BhjXQP9dAtxD09jHjdRi9ewr5NXcAxBGo82HYvvwu6T-yPwDbTb7F</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2678988333</pqid></control><display><type>article</type><title>Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study</title><source>Social Science Premium Collection</source><source>Sociology Collection</source><source>Springer Link</source><creator>Pedersini, Rebecca ; Zamparini, Manuel ; Bosio, Sara ; di Mauro, Pierluigi ; Turla, Antonella ; Monteverdi, Sara ; Zanini, Alessandra ; Amoroso, Vito ; Vassalli, Lucia ; Cosentini, Deborah ; Grisanti, Salvatore ; Simoncini, Edda Lucia ; Berruti, Alfredo</creator><creatorcontrib>Pedersini, Rebecca ; Zamparini, Manuel ; Bosio, Sara ; di Mauro, Pierluigi ; Turla, Antonella ; Monteverdi, Sara ; Zanini, Alessandra ; Amoroso, Vito ; Vassalli, Lucia ; Cosentini, Deborah ; Grisanti, Salvatore ; Simoncini, Edda Lucia ; Berruti, Alfredo</creatorcontrib><description>Purpose
Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients’ quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospectively evaluate the characteristics of TAs in early breast cancer (EBC) patients during (neo)adjuvant chemotherapy and up to 1 year after its completion.
Methods
From April 2014 to June 2018, 182 EBC patients entered the study and received (neo)adjuvant chemotherapy, mostly with taxane and anthracycline-containing regimens (65% of cases). A dietitian performed TAs assessment through the Common Terminology Criteria for Adverse Event v4.0 (CTCAE) and the Chemotherapy-induced Taste Alteration Scale (CiTAS) questionnaire during chemotherapy and follow-up according to defined time points: at baseline (T0, before starting chemotherapy); at the first follow-up visit, (T1, 2 months after starting chemotherapy); at the final follow-up visit (T2, 1 week after completing chemotherapy); after that, every 3 months up to 12 months.
Results
Dysgeusia was reported by 69.8% of patients at T1 and declined subsequently; salty flavor distortion was the most frequently reported TA (51.6% of cases). CiTAS was significantly different between T0 and T2 (
p
< 0.001). Dysgeusia occurred more frequently in patients reporting nausea, mucositis, diarrhea, and appetite modification.
Conclusions
TAs are common but transient during chemotherapy and occurred frequently with other distressing gastrointestinal side effects. The assessment of these side effects is crucial in managing EBC patients during (neo)adjuvant chemotherapy.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-022-07091-6</identifier><identifier>PMID: 35538327</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adjuvant treatment ; Anthracyclines ; Breast cancer ; Cancer ; Cancer patients ; Care and treatment ; Chemosensory perception ; Chemotherapy ; Clinical trials ; Medicine ; Medicine & Public Health ; Nausea ; Nursing ; Nursing Research ; Oncology ; Oncology, Experimental ; Original Article ; Pain Medicine ; Rehabilitation Medicine ; Side effects ; Taste ; Taste disorders ; Terminology</subject><ispartof>Supportive care in cancer, 2022-08, Vol.30 (8), p.6955-6961</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2876-6e3db47b557978daf8dfc9f16f6aa3cb322fdf18b644d247195070aa808da903</citedby><cites>FETCH-LOGICAL-c2876-6e3db47b557978daf8dfc9f16f6aa3cb322fdf18b644d247195070aa808da903</cites><orcidid>0000-0001-5357-5703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2678988333/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2678988333?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,21375,21376,27903,27904,33590,33591,34509,34510,43712,44094,73967,74385</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35538327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pedersini, Rebecca</creatorcontrib><creatorcontrib>Zamparini, Manuel</creatorcontrib><creatorcontrib>Bosio, Sara</creatorcontrib><creatorcontrib>di Mauro, Pierluigi</creatorcontrib><creatorcontrib>Turla, Antonella</creatorcontrib><creatorcontrib>Monteverdi, Sara</creatorcontrib><creatorcontrib>Zanini, Alessandra</creatorcontrib><creatorcontrib>Amoroso, Vito</creatorcontrib><creatorcontrib>Vassalli, Lucia</creatorcontrib><creatorcontrib>Cosentini, Deborah</creatorcontrib><creatorcontrib>Grisanti, Salvatore</creatorcontrib><creatorcontrib>Simoncini, Edda Lucia</creatorcontrib><creatorcontrib>Berruti, Alfredo</creatorcontrib><title>Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients’ quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospectively evaluate the characteristics of TAs in early breast cancer (EBC) patients during (neo)adjuvant chemotherapy and up to 1 year after its completion.
Methods
From April 2014 to June 2018, 182 EBC patients entered the study and received (neo)adjuvant chemotherapy, mostly with taxane and anthracycline-containing regimens (65% of cases). A dietitian performed TAs assessment through the Common Terminology Criteria for Adverse Event v4.0 (CTCAE) and the Chemotherapy-induced Taste Alteration Scale (CiTAS) questionnaire during chemotherapy and follow-up according to defined time points: at baseline (T0, before starting chemotherapy); at the first follow-up visit, (T1, 2 months after starting chemotherapy); at the final follow-up visit (T2, 1 week after completing chemotherapy); after that, every 3 months up to 12 months.
Results
Dysgeusia was reported by 69.8% of patients at T1 and declined subsequently; salty flavor distortion was the most frequently reported TA (51.6% of cases). CiTAS was significantly different between T0 and T2 (
p
< 0.001). Dysgeusia occurred more frequently in patients reporting nausea, mucositis, diarrhea, and appetite modification.
Conclusions
TAs are common but transient during chemotherapy and occurred frequently with other distressing gastrointestinal side effects. The assessment of these side effects is crucial in managing EBC patients during (neo)adjuvant chemotherapy.</description><subject>Adjuvant treatment</subject><subject>Anthracyclines</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Care and treatment</subject><subject>Chemosensory perception</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nausea</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Rehabilitation Medicine</subject><subject>Side effects</subject><subject>Taste</subject><subject>Taste disorders</subject><subject>Terminology</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2R</sourceid><sourceid>M2S</sourceid><recordid>eNp9kstu1DAUhi0EotPCC7BAltiwcetb4oRdVUFBqsRm9pbjS-uR4wQ7KZrH6BtzhilFIIS9sHTOd36fG0JvGD1nlKqLSmnDKaGcE6poz0j7DG2YFIIoIfrnaEN7yYgUTXOCTmvdUcqUavhLdAIm0QmuNuhha-risUmLL2aJU67YrSXmW5z9dGHcbr03ecH2zo_TcgfMvMcmO1zXofpvqwdfmFKavpN1xjHjoXgQxNZk6wueQRKQ-gEbPJepzt4u8d7jCh8kTyz4gLIp5mhNwnVZ3f4VehFMqv7143uGtp8-bq8-k5uv11-uLm-I5Z1qSeuFG6Qamkb1qnMmdC7YPrA2tMYIOwjOgwusG1opHZeK9Q00yZiOAtxTcYbeH2UhL6ijLnqM1fqUDBS-Vs3blkOTpOwAffcXupvWkiE5oFTXd52A80TdmuR1zGFairEHUX2pqOqlYIoBdf4PCq7zY7RT9iGC_Y8Afgyw0L9afNBziaMpe82oPqyBPq6BhjXQP9dAtxD09jHjdRi9ewr5NXcAxBGo82HYvvwu6T-yPwDbTb7F</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Pedersini, Rebecca</creator><creator>Zamparini, Manuel</creator><creator>Bosio, Sara</creator><creator>di Mauro, Pierluigi</creator><creator>Turla, Antonella</creator><creator>Monteverdi, Sara</creator><creator>Zanini, Alessandra</creator><creator>Amoroso, Vito</creator><creator>Vassalli, Lucia</creator><creator>Cosentini, Deborah</creator><creator>Grisanti, Salvatore</creator><creator>Simoncini, Edda Lucia</creator><creator>Berruti, Alfredo</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5357-5703</orcidid></search><sort><creationdate>20220801</creationdate><title>Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study</title><author>Pedersini, Rebecca ; Zamparini, Manuel ; Bosio, Sara ; di Mauro, Pierluigi ; Turla, Antonella ; Monteverdi, Sara ; Zanini, Alessandra ; Amoroso, Vito ; Vassalli, Lucia ; Cosentini, Deborah ; Grisanti, Salvatore ; Simoncini, Edda Lucia ; Berruti, Alfredo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2876-6e3db47b557978daf8dfc9f16f6aa3cb322fdf18b644d247195070aa808da903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adjuvant treatment</topic><topic>Anthracyclines</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Care and treatment</topic><topic>Chemosensory perception</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nausea</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Rehabilitation Medicine</topic><topic>Side effects</topic><topic>Taste</topic><topic>Taste disorders</topic><topic>Terminology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pedersini, Rebecca</creatorcontrib><creatorcontrib>Zamparini, Manuel</creatorcontrib><creatorcontrib>Bosio, Sara</creatorcontrib><creatorcontrib>di Mauro, Pierluigi</creatorcontrib><creatorcontrib>Turla, Antonella</creatorcontrib><creatorcontrib>Monteverdi, Sara</creatorcontrib><creatorcontrib>Zanini, Alessandra</creatorcontrib><creatorcontrib>Amoroso, Vito</creatorcontrib><creatorcontrib>Vassalli, Lucia</creatorcontrib><creatorcontrib>Cosentini, Deborah</creatorcontrib><creatorcontrib>Grisanti, Salvatore</creatorcontrib><creatorcontrib>Simoncini, Edda Lucia</creatorcontrib><creatorcontrib>Berruti, Alfredo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pedersini, Rebecca</au><au>Zamparini, Manuel</au><au>Bosio, Sara</au><au>di Mauro, Pierluigi</au><au>Turla, Antonella</au><au>Monteverdi, Sara</au><au>Zanini, Alessandra</au><au>Amoroso, Vito</au><au>Vassalli, Lucia</au><au>Cosentini, Deborah</au><au>Grisanti, Salvatore</au><au>Simoncini, Edda Lucia</au><au>Berruti, Alfredo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>30</volume><issue>8</issue><spage>6955</spage><epage>6961</epage><pages>6955-6961</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients’ quality of life; however, the prevalence, types, and duration of TAs and their potential relationship with other clinical disturbances are not well-described. Our primary aim was to prospectively evaluate the characteristics of TAs in early breast cancer (EBC) patients during (neo)adjuvant chemotherapy and up to 1 year after its completion.
Methods
From April 2014 to June 2018, 182 EBC patients entered the study and received (neo)adjuvant chemotherapy, mostly with taxane and anthracycline-containing regimens (65% of cases). A dietitian performed TAs assessment through the Common Terminology Criteria for Adverse Event v4.0 (CTCAE) and the Chemotherapy-induced Taste Alteration Scale (CiTAS) questionnaire during chemotherapy and follow-up according to defined time points: at baseline (T0, before starting chemotherapy); at the first follow-up visit, (T1, 2 months after starting chemotherapy); at the final follow-up visit (T2, 1 week after completing chemotherapy); after that, every 3 months up to 12 months.
Results
Dysgeusia was reported by 69.8% of patients at T1 and declined subsequently; salty flavor distortion was the most frequently reported TA (51.6% of cases). CiTAS was significantly different between T0 and T2 (
p
< 0.001). Dysgeusia occurred more frequently in patients reporting nausea, mucositis, diarrhea, and appetite modification.
Conclusions
TAs are common but transient during chemotherapy and occurred frequently with other distressing gastrointestinal side effects. The assessment of these side effects is crucial in managing EBC patients during (neo)adjuvant chemotherapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35538327</pmid><doi>10.1007/s00520-022-07091-6</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5357-5703</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2022-08, Vol.30 (8), p.6955-6961 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2662538448 |
| source | Social Science Premium Collection; Sociology Collection; Springer Link |
| subjects | Adjuvant treatment Anthracyclines Breast cancer Cancer Cancer patients Care and treatment Chemosensory perception Chemotherapy Clinical trials Medicine Medicine & Public Health Nausea Nursing Nursing Research Oncology Oncology, Experimental Original Article Pain Medicine Rehabilitation Medicine Side effects Taste Taste disorders Terminology |
| title | Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T22%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Taste%20alterations%20during%20neo/adjuvant%20chemotherapy%20and%20subsequent%20follow-up%20in%20breast%20cancer%20patients:%20a%20prospective%20single-center%20clinical%20study&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Pedersini,%20Rebecca&rft.date=2022-08-01&rft.volume=30&rft.issue=8&rft.spage=6955&rft.epage=6961&rft.pages=6955-6961&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-022-07091-6&rft_dat=%3Cgale_proqu%3EA707943171%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2876-6e3db47b557978daf8dfc9f16f6aa3cb322fdf18b644d247195070aa808da903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2678988333&rft_id=info:pmid/35538327&rft_galeid=A707943171&rfr_iscdi=true |